Earnings per Share (EPS) prediction for the fourth quarter is $0.78 with revenue expectations of approximately $4.42 billion.
FLR has had a mixed performance over the past four quarters, exceeding earnings expectations twice and missing twice.
The company’s price-to-earnings (P/E) ratio is 28.54, indicating a high market valuation of its earnings, while its price-to-sales ratio of 0.47 suggests a lower market valuation relative to sales.
Fluor Corporation, listed on the NYSE:FLR, is a global engineering and construction firm operating in three main segments: Energy & Chemicals, Infrastructure & Power, and Government. As FLR prepares to release its fourth-quarter 2024 earnings on February 18, 2025, analysts predict an earnings per share (EPS) of $0.78 and revenue of approximately $4.42 billion.
In the previous quarter, FLR’s adjusted EPS and revenues fell short of the Zacks Consensus Estimate by 34.6% and 14.6%, respectively. Despite these misses, the company saw a 3.3% year-over-year revenue increase. However, net income dropped by 50%, highlighting challenges in maintaining profitability. Over the past four quarters, FLR has exceeded earnings expectations twice and missed them twice.
The Zacks Consensus Estimate for FLR’s fourth-quarter EPS was recently adjusted from $0.79 to $0.78, still marking a 14.7% increase from the previous year’s $0.68. This adjustment reflects cautious optimism about FLR’s performance. The company’s price-to-earnings (P/E) ratio of 28.54 suggests a high market valuation of its earnings, while a price-to-sales ratio of 0.47 indicates a relatively low market valuation compared to sales.
FLR’s enterprise value to sales ratio of 0.36 and enterprise value to operating cash flow ratio of 6.98 highlight its modest valuation and cash flow efficiency. The earnings yield of 3.50% provides insight into the return on investment for shareholders. With a debt-to-equity ratio of 0.50, FLR maintains a balanced approach to leveraging debt, and a current ratio of 1.77 indicates strong short-term financial health.
